Functional role of the translocator protein 18 kDa (TSPO) in depressive patients under electroconvulsive therapy (ECT)

Medizinische Einrichtungen des Bezirks Oberpfalz0 个研究点目标入组 9 人开始时间: 2021年12月7日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Consenting female and male patients aged 18-60 years.
•-Inpatients with a depressive episode (ICD-10 F31, F32, F33; HAMD-21: =17).
•-Only after the study procedure has been fully and thoroughly explained and patients have given written informed consent will they be included in the study.

•-Pregnant or breastfeeding women
•-Drug or alcohol dependence
•-Depressive episode secondary to somatic/neurological disease or substance dependence
•-Severe neurological or internistic concomitant disease that may falsify the examination results (e.g. fresh myocardial infarction, Cushing's disease, underlying rheumatic diseases)
•-Other additional severe psychiatric comorbidities
•-The patient cannot understand the nature and scope of the study and is therefore not capable of giving consent.
•-Enrolment not voluntary
•-Regular systemic use of steroids or non-steroidal anti-inflammatory drugs (NSAID).
•-Incompatibility with MR measurement (MR questionnaire)

发起方

Medizinische Einrichtungen des Bezirks Oberpfalz